S63845 CAS No.:1799633-27-4

S63845 CAS No.:1799633-27-4: The Future of Cancer Treatment

S63845 is a revolutionary cancer treatment drug that is capable of targeting cancers that have evolved a specific resistance to other forms of chemotherapy medication. It is a highly effective drug that is designed to target cancers at the molecular level, thus reducing the risk of damage to healthy cells and tissues.

S63845 has been developed by scientists in China and has been clinically tested with promising results. As a manufacturer located in China, we are proud to offer this innovative drug to merchants around the world who are looking to expand their portfolio of cancer treatments.

What makes S63845 so unique is its ability to target the molecular mechanisms that allow the cancer to evade other forms of medication. Most cancer medications target the entire tumor rather than specific molecular pathways. S63845 targets a specific protein known as MDMX, which is responsible for the amplification of a variety of cancer-causing genes.

By targeting this specific protein, S63845 has been shown to be effective in the treatment of cancers that have not responded to other therapies. As a result, this drug has the potential to become a mainstay of cancer treatment, particularly for those who have exhausted all other treatment options.

S63845 is currently undergoing clinical trials and has already shown promising results. In a recent study, S63845 was tested on mice with human neuroblastoma tumors that had developed resistance to the commonly used chemotherapy drug cyclophosphamide. The results showed that S63845 was highly effective in inhibiting the growth of these tumors.

This success has led to further studies being conducted to determine how effective S63845 could be in treating other types of cancer. Currently, studies are ongoing to determine its efficacy in treating lung, breast, and colon cancers.

Apart from its effectiveness, another positive aspect of S63845 is that it has very few side effects. This is because the drug is specifically designed to target cancer cells at the molecular level, leaving healthy cells and tissues unharmed. This makes S63845 a viable option for patients who could not tolerate other types of cancer treatment due to their severe side effects.

As a manufacturer, we can vouch for the quality of S63845. We have ensured that our production process adheres to strict quality control measures, ensuring consistent and reliable results. Our team of scientists has worked tirelessly to ensure that the drug is of the highest standard possible.

In conclusion, S63845 is a highly effective and innovative cancer treatment drug that has shown great promise in terms of its effectiveness and safety. As a manufacturer located in China, we are proud to offer this product to merchants around the world who are looking to expand their portfolio of cancer treatments. With its promising clinical results, it is clear that S63845 has the potential to change the lives of millions of people around the world.

Chemical Structure : S-63845

CAS No.: 1799633-27-4

 

S-63845(S 63845;S63845)

Catalog No.: URK-V734  Only Used For Lab.

S-63845 (S63845) is a highly potent, selective Mcl-1 inhibitor with Kd of 0.19 nM, with no appreciable binding affinity to BCL-2 or BCL-XL (Ki>10 uM).

Biological Activity

S-63845 (S63845) is a highly potent, selective Mcl-1 inhibitor with Kd of 0.19 nM, with no appreciable binding affinity to BCL-2 or BCL-XL (Ki>10 uM); binds to the BH3-binding groove of Mcl-1, potently kills MCL1-dependent cancer cells, including multiple myeloma (IC50<0.1 uM), leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway; is well tolerated and shopws high effectivity against mouse cancer models.
Blood Cancer
Preclinical

Physicochemical Properties

References

1. Kotschy A, et al. Nature. 2016 Oct 27;538(7626):477-482.

2. Merino D, et al. Sci Transl Med. 2017 Aug 2;9(401). pii: eaam7049.

3. Letai A. Cancer Cell. 2016 Dec 12;30(6):834-835.

URK-V734_COA

URK-V734_SDS

URK-V734_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• Our track record of success and positive customer feedback speaks for itself.
• The company has very rich practical experience in the manufacturing field of S63845 CAS No.:1799633-27-4, and aims at the market and tracks the world’s advanced technology level, relying on a sound management system and after-sales service, and with an honest, trustworthy, stable attitude and reliable Quality, reasonable price, and strive to provide customers with satisfactory products.
• Our Apoptosis Library products are designed to meet the needs of researchers in the field.
• Our core business philosophy is sincerity-based and excellence, because integrity is the way to be a person, the foundation of one's identity, and the first key to business philosophy.
• Our customers can expect exceptional service and prompt delivery of their orders.
• Our company accelerates the development to realize the value of the enterprise itself, to meet the needs of the market, and to drive the benign development of related industries.
• Our mission is to help researchers achieve their goals by providing them with the best possible resources.
• Our experience makes us important in our customer eyes.
• Our Apoptosis Library products are reliable and dependable.
• We have always attached great importance to the cultivation of talents and the construction of high-tech talent team.

Hot Tags: s63845 cas no.:1799633-27-4, China s63845 cas no.:1799633-27-4, epigenetic library for epigenetic analysis of non coding rna, agonists for joint repair, agonists for antioxidant activity, epigenetic library for epigenetic amplification, inhibitors for exocytosis, epigenetic library for epigenetic resilience